8-K: IN8bio Reports Positive Clinical Trial Data and Secures $11.6 Million in Private Placement

IN8bio announced positive clinical trial results for its INB-100 therapy, along with a $11.6 million private placement to extend its cash runway into 2026.

Summary

• IN8bio reported its third quarter 2024 financial results and provided corporate updates.
• The company highlighted that 100% of Acute Myeloid Leukemia (AML) patients treated with INB-100 remain in complete remission.
• IN8bio received FDA guidance for a potential registrational trial for INB-100.
• The company closed a private placement for $11.6 million in net proceeds, extending its cash runway into the first quarter of 2026.
• IN8bio is expanding enrollment in the INB-100 trial to approximately 25 patients and may add additional centers and a control cohort.
• The company has streamlined operations and prioritized its pipeline, including suspending further development of INB-400.
• Research and Development expenses decreased to $3.3 million, while General and Administrative expenses decreased to $2.7 million.
• The net loss for the quarter was $7.1 million, or $0.15 per share.
• As of September 30, 2024, the company had $4.0 million in cash, which was subsequently boosted by the private placement.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and secures significant funding, which is very encouraging. However, the workforce reduction and suspension of one trial temper the overall sentiment slightly.

Positives

• The INB-100 trial shows 100% complete remission in AML patients.
• FDA guidance provides a clear path for a potential registrational trial for INB-100.
• The $11.6 million private placement extends the cash runway into the first quarter of 2026.
• The company is focusing on the most promising programs and streamlining operations.
• INB-100 has demonstrated significant in vivo expansion and long-term persistence of gamma-delta T cells.
• INB-100 has exceeded expected progression-free survival rates in high-risk leukemia patients.

Negatives

• The company has suspended further clinical development of INB-400.
• A strategic workforce reduction was implemented in the third quarter of 2024.
• The company reported a net loss of $7.1 million for the quarter.
• Cash reserves decreased to $4.0 million before the private placement.

Risks

• There are risks to site initiation, clinical trial commencement, patient enrollment and follow-up.
• The company may be unable to raise additional capital and could be forced to delay or terminate development programs.
• There is uncertainty in the regulatory approval process for trials and marketing products.
• The company relies on third parties, including licensors and clinical research organizations.
• The outcomes of preclinical studies may not be predictive of clinical trial results.

Future Outlook

The company expects the $11.6 million private placement to provide cash runway into the first quarter of 2026. They plan to continue advancing INB-100 and seek potential partnerships for other pipeline assets. They also plan to present updated data at future medical meetings.

Management Comments

• William Ho, CEO and co-founder of IN8bio, stated that the past quarter marked a critical moment for IN8bio, with streamlined operations and a refined pipeline.
• He also mentioned that the strategic realignment enhances the company's capacity to deliver on the potential of gamma-delta T cell therapies.
• Management believes the FDA guidance provides a clear path forward for a potential registrational trial for INB-100.

Industry Context

The announcement highlights the growing interest in gamma-delta T cell therapies for cancer treatment. The positive clinical data for INB-100 positions IN8bio as a key player in this emerging field. The company's focus on allogeneic therapies also aligns with the industry's push for more accessible and scalable treatments.

Comparison to Industry Standards

• The reported 100% complete remission rate in AML patients treated with INB-100 is a very positive result compared to standard treatments and other experimental therapies.
• The company's ability to secure $11.6 million in private placement funding is a positive sign of investor confidence, especially in the current biotech funding environment.
• The suspension of the INB-400 trial is not uncommon in the biotech industry, where companies often need to prioritize resources and focus on the most promising programs.
• The reported one-year progression-free survival rate exceeding 40-50% post-haploidentical transplantation is a positive result compared to historical benchmarks for high-risk leukemia patients.

Stakeholder Impact

• Shareholders will likely view the positive clinical data and funding as positive developments.
• Employees may be impacted by the workforce reduction.
• Patients with AML may benefit from the continued development of INB-100.
• The company's focus on gamma-delta T cell therapies could impact the broader cancer treatment landscape.

Next Steps

• IN8bio will continue enrollment in the Phase 1 expansion cohort of INB-100.
• The company plans to potentially add additional centers and a parallel observational arm to the INB-100 trial.
• IN8bio will present updated clinical trial results from INB-200 at the Society for Neuro-Oncology (SNO) in November 2024.
• A poster presentation updating patient data from the INB-100 trial will be presented at the American Society of Hematology (ASH) in December 2024.
• The company will continue monitoring previously treated GBM patients in both the Phase 2 INB-400 and the Phase 1 INB-200 clinical trials to assess progression-free and overall survival.

Key Dates

Keywords

IN8bio, Gamma-delta T cells, Immunotherapy, AML, INB-100, Clinical Trial, Private Placement, FDA Guidance, Leukemia, Cancer